WINT News and Press, Windtree Therapeutics Inc. From 11/16/20

Windtree Therapeutics (WINT): Q3 GAAP EPS of -$0.54.Press Release For further details see: Windtree Therapeutics reports Q3 results

Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates PR Newswire WARRINGTON, Pa., Nov. 16, 2020 WARRINGTON, Pa. , Nov. 16, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology ...

Windtree Therapeutics (WINT) has dosed the first patient in its Phase 2 study of istaroxime in patients experiencing early cardiogenic shock, a life-threatening state of lack of heart function and blood flow to vital organs.The 60-subject study's primary endpoint is the change in systolic blo...

Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients Study Opens a New, Additional Area of Development for Istaroxime PR Newswire WARRINGTON, Pa., Oct. 1, 2020 WARRING...

Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon...

Gainers: Adial Pharmaceuticals (ADIL) +33%, Spero Therapeutics (SPRO) +16%, LogicBio Therapeutics (LOGC) +14%, AngioDynamics (ANGO) +14%, Windtree Therapeutics (WINT) +10%.Losers: Myovant Sciences (MYOV) -21%, TransMedics Group (TMDX...

The FDA signs off Phase 2 trial of Windtree Therapeutics's (WINT) lyo lucinactant, KL4 surfactant drug for the treatment of COVID-19 associated lung injury and acute respiratory distress syndrome patients.The 20-subject trial is expected to commence within the next several week...

U.S. Energy (USEG) +168% after entering producing assets purchase agreement.Houston American Energy (HUSA) +77%.PEDEVCO (PED) +56%.Greenpro Capital Corp. (GRNQ) +53%.Flux Power Holdings (FLUX) +36% on FY results.Mexco Energy (MXC) +33%.Westwater Resources (WWR) +30%.New Co...

Windtree Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 Company Provides Update on COVID-19 Program PR Newswire WARRINGTON, Pa., Sept. 29, 2020 WARRINGTON, Pa. , ...

WARRINGTON, Pa. , Sept. 8, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Frasier, presid...